Please login to the form below

Not currently logged in
Email:
Password:

Janssen/Jubilant alliance

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience.

The alliance, which will see Jubliant develop preclinical drug clients for Janssen to develop and commercialise, is set to last at least three years.

Jubilant is to receive research funding and is eligible for future milestones and royalties depending on the success of drug candidates.

Financial terms were not disclosed.

"The collaboration will utilise Jubilant's global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres," said Sri Mosur, CEO and president, global drug discovery and development, Jubilant.

"We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry."

28th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics